Tag: FDA-approved ovarian drugs 2024

Home / FDA-approved ovarian drugs 2024

Categories

Mirvetuximab soravtansine-gynx is approved by the USFDA for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

March 2024: The Food and Drug Administration has granted approval for mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) to be used in adult patients with FRα positive, ...
fda-approved-ovarian-drugs-2024

Scan the code